Close Menu

Immunotherapy

News and reporting on cancer immunotherapy.

Revenue growth in Q2 was driven by strong sales of the company's Panorama noninvasive prenatal test and Horizon carrier screening test.

The company recently said it was discontinuing development of its original and only in-house developed assay after a failed clinical validation.

A consortium convened by Friends of Cancer Research has made progress in quantifying sources of TMB assay discordance and created a new test-alignment software tool.

The company expects to garner clearance for its platform in the US first for Lynch syndrome as it builds additional evidence for an immunotherapy application.

The firm has collected important health economic evidence for its clinical lung cancer assay and is building evidence for other products in additional cancer types.

Two recent acquisitions have resulted in the swift launch of two assays, one for the clinic and another for research use, as the firm's original test finally nears validation.

The groups have written draft recommendations and are now asking for public comment from pathologists and other stakeholders.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.

The company is using the test to direct patient enrollment and treatment stratification in a trial of pembrolizumab (Keytruda) combination treatments.

Pages